WO2025080565 - LOW-SUGAR CORONAVIRUS VACCINE AND METHODS THEREOF
National phase entry:
Publication Number
WO/2025/080565
Publication Date
17.04.2025
International Application No.
PCT/US2024/050353
International Filing Date
08.10.2024
Title **
[English]
LOW-SUGAR CORONAVIRUS VACCINE AND METHODS THEREOF
[French]
VACCIN CONTRE LE CORONAVIRUS À FAIBLE TENEUR EN SUCRE ET PROCÉDÉS ASSOCIÉS
Applicants **
ROCK BIOMEDICAL, INC.
LEE, Jeng-Shin
Inventors
WU, Chung-Yi
WONG, Chi-Huey
Priority Data
63/588,932
09.10.2023
US
63/549,343
02.02.2024
US
63/575,093
05.04.2024
US
PCT/US2024/023597
08.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3665 | |
| EPO | Filing, Examination, Granting | 23076 | |
| Japan | Filing, Examination, Granting | 2618 | |
| South Korea | Filing, Examination, Granting | 3232 | |
| USA | Filing, Examination, Granting | 7210 |
Total:
39,801
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.[French]
La présente divulgation concerne une protéine de spicule faiblement glycosylée et un vaccin conçu pour exprimer la protéine de spicule in vivo. La présente divulgation concerne également un procédé de production d'une réponse immunitaire à l'aide de la protéine de spicule faiblement glycosylée, qui fournit une protection plus large sur différentes variantes. L'invention concerne également un procédé d'identification d'un peptide conservé protégé contre les glycanes d'une glycoprotéine.